about
Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe.Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009Use of neonatal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV is decreasing in Western Europe.Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.Within and between race differences in lymphocyte, CD4+, CD8+ and neutrophil levels in HIV-uninfected children with or without HIV exposure in Europe and Uganda.The influence of assisted reproduction on family functioning and children's socio-emotional development: results from a European study.Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers.Risk factors for mother-to-child transmission of HIV-1.Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study.Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys?Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life.Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women.Levels and patterns of HIV RNA viral load in untreated pregnant women.Age-related standards for total lymphocyte, CD4+ and CD8+ T cell counts in children born in Europe.Height, weight, and growth in children born to mothers with HIV-1 infection in Europe.Older children and adolescents surviving with vertically acquired HIV infection.Pregnancy-related changes in the longer-term management of HIV-infected women in Europe.Management of vertically HIV-infected children in Europe.CD4 Cell Response to Antiretroviral Therapy in Children with Vertically Acquired HIV Infection: Is It Associated with Age at Initiation?Does Exposure to Antiretroviral Therapy Affect Growth in the First 18 Months of Life in Uninfected Children Born to HIV-Infected Women?Does Highly Active Antiretroviral Therapy Increase the Risk of Congenital Abnormalities in HIV-Infected Women?Are girls more at risk of intrauterine-acquired HIV infection than boys?Are There Gender and Race Differences in Cellular Immunity Patterns Over Age in Infected and Uninfected Children Born to HIV-Infected Women?Combination antiretroviral therapy and duration of pregnancyIs zidovudine therapy in pregnant HIV-infected women associated with gestational age and birthweight?Increasing likelihood of further live births in HIV-infected women in recent yearsThe mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West
P50
Q34387805-1B569586-6CCD-4ACB-B981-460CD896721AQ34615517-01B29238-E48F-420F-B89C-4BD629B538E8Q35869263-C92972A7-8E6E-49F8-836F-7465ED543AB7Q36193276-0B882E56-ACD8-4D9A-B11C-8E1D0EAD1DBBQ36193307-710B77CF-DBD4-456A-B2A5-CFE58E3FC4C7Q38879127-1B5D4E37-47F8-4999-958D-4D3F803F6291Q40515248-55DE35DB-489D-4E04-895D-B27CA55BB7A6Q43793133-32137A80-3CB5-45F2-A995-69023F3B2E1FQ43819681-9FC9E9D5-5D7F-4CC8-BD13-D05630C7DCAFQ44883223-FBDE1A41-94F9-4381-A312-E8501AAA0F0DQ44951422-AE9964A3-8E99-4462-AE02-CC18F8559470Q45200184-A51B349D-66A5-459A-B09B-9011FC48AA0BQ45736678-FE9A15F8-4A42-4D5A-B180-D1D559AC3758Q46240838-3FCEE579-4E23-4559-8032-AF8F0DC13BC6Q46450661-F35D39A5-B4AD-4E6A-B1B2-3EBACB47C096Q46675855-8ED719C3-D6E7-4C7E-9BDD-8659157D9026Q47173963-324A6C0E-E4D3-493D-8F76-75DAFB8470D9Q47615049-F74E1BA9-C596-4DDE-9671-94E212A80DF6Q47862350-C0373324-8678-4A55-868E-C8D1B169C488Q47956934-221B21DC-6938-401E-9D77-17ADF5C28876Q56837465-48B0EC53-929E-42B1-928C-98F0C10CE0DAQ56837476-35A2BABC-DE7B-4029-9256-05D583955148Q56837478-BA2B82FD-16A0-4520-99B4-14E26E9CDACEQ56837506-AEF2D318-91D9-4E74-A80F-24E22CDA8CB6Q56837534-6DA8FC61-CAC8-41DA-9C8E-0B4AD5DC40BEQ56837586-3E47FEE4-8B99-4211-BA50-AF8B0206E320Q56837594-5732B21F-80C3-4C3B-ACD2-450F3F168460Q57076245-FFBC52D1-07E8-46CE-B0B6-76EB25F87EF6Q79767564-137D6EC8-B459-405F-87CA-7DF47CADA2A1
P50
name
European Collaborative Study
@en
type
label
European Collaborative Study
@en
prefLabel
European Collaborative Study
@en